Manuela A. Joore

Maastricht, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

Risk-based selection for carotid revascularisation using the IMPROVE score versus standard care in symptomatic carotid artery disease: a model-based cost-effectiveness analysis using pooled-data.

Risk-based selection for carotid revascularisation using the IMPROVE score versus standard care in symptomatic carotid artery disease: a model-based cost-effectiveness analysis using pooled-data.

Journal: BMJ open

Published: May 28, 2026

SMART Planning of Early-Stage Health Economic Decision Models for Mechanism-Based Precision Treatments in Rare Cancers: An Application and Tool Update.

SMART Planning of Early-Stage Health Economic Decision Models for Mechanism-Based Precision Treatments in Rare Cancers: An Application and Tool Update.

Journal: PharmacoEconomics

Published: March 05, 2026

From procurement to disposal: a framework for an activity-based cost analysis of reusable and disposable trocars in laparoscopic cholecystectomy.

From procurement to disposal: a framework for an activity-based cost analysis of reusable and disposable trocars in laparoscopic cholecystectomy.

Journal: Surgical endoscopy

Published: February 04, 2026

Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer.

Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer.

Journal: Clinical and translational radiation oncology

Published: January 27, 2026

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.

Journal: PharmacoEconomics

Published: November 20, 2025

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Journal: PharmacoEconomics

Published: November 17, 2025

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: September 25, 2025

Cost-effectiveness analysis of the Assessment of Burden of Chronic Conditions (ABCC) tool in primary care in the Netherlands.

Cost-effectiveness analysis of the Assessment of Burden of Chronic Conditions (ABCC) tool in primary care in the Netherlands.

Journal: BMJ open

Published: June 24, 2025

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

Journal: Clinical drug investigation

Published: June 04, 2025

Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool.

Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool.

Journal: PharmacoEconomics

Published: May 29, 2025

Bilateral vestibulopathy - insight in impact on quality of life and economic burden.

Bilateral vestibulopathy - insight in impact on quality of life and economic burden.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Published: April 14, 2025

Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical Outcome.

Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical Outcome.

Journal: The Journal of investigative dermatology

Published: March 19, 2025

Showing 1-12 of 184

Last Updated: 09/26/2026